Loading...

Follow C17 Council Blog on Feedspot

Continue with Google
Continue with Facebook
or

Valid

Dear Alberta Based SKIP Partners and Friends:

We have a full-time Solutions for Kids in Pain (SKIP) Knowledge Broker position based at Stollery Children’s/University of Alberta, supervised by our amazing Edmonton-based SKIP Hub lead Dr. Samina Ali.  The posting ends June 20th.  Can you help us spread the word? This is a great employment opportunity for the right person!

A minimum of Bachelor’s Level education in a relevant discipline (e.g., science, health administration, communication, or equivalent); Master’s degree preferred

Complete position description can be found at:

https://www.careers.ualberta.ca/Competition/S100839204/

https://www.linkedin.com/jobs/view/skip-knowledge-broker-edmonton-at-university-of-alberta-1320660364/

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Please see the complete job posting at: https://cusm.njoyn.com/cl3/xweb/Xweb.asp?tbtoken=ZVpaRB4XCG1xZXN0TVVUCCNLAxdEcCJZAUhZVFEJExEpKjZvKEITdWAGdwkbURBQTXIqWA%3D%3D&chk=dFlbQBJe&CLID=55242&page=jobdetails&JobID=J0519-1247&brid=20082&lang=1

RESEARCH INSTITUTE OF THE MUHC

The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and hospital research centre. Located in Montreal, Quebec, the Institute is the research arm of the McGill University Health Centre (MUHC) affiliated with the Faculty of Medicine at McGill University. The RI-MUHC is supported in part by the Fonds de recherche du Québec – Santé (FRQS).

Position summary

The MUHC Pediatric Hematology/Oncology Research Program aims to promote and improve the health of children and young adults diagnosed with cancer or hematological disorders. We support and conduct research and research training in health and illness with the goal of facilitating the development and implementation of clinical trials, biobanks, cancer control, and nurse-initiated studies and protocols. Ongoing efforts to strengthen the interdisciplinary aspects of research are a priority for us. 

The purpose of this job is to initiate and coordinate clinical trials according to regulatory and institutional guidelines and requirements, register eligible participants, manage the studies, extract, compile and submit data, monitor study compliance, monitor and maintain on-going regulatory requirements, provide information and feedback on designated clinical trial studies. 

Education / Experience
  • Work experience: Minimum of two (2) years of experience in clinical research. Certified Clinical Research Professional (through SoCRA or ACRP or equivalent organization) preferred,
  • Education: Minimum of a DEC in nursing (Registered Nurse), 
  • Good standing with the OIIQ,
  • Excellent communication skills in French and English, spoken and written,
  • Strong analytical skills and ability to synthesize complex material clearly,
  • Excellent interpersonal and leadership skills,
  • Ability to work effectively in a team and autonomously,
  • Exceptional organizational skills, meticulous and detail-oriented,
  • Motivated and enthusiastic,
  • Able to work in an environment with children and young adults with cancer,
  • Comprehensively use computer software and technology
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Find instructions for abstract submission here: 
https://conference.ccra-acrc.ca/abstracts/

The Canadian Cancer Research Conference provides an excellent opportunity to present pediatric/AYA research to the cancer community. Abstract submissions from the entire spectrum of research topics are welcome. Trainees (undergraduate students, graduate students, and postdoctoral fellows) and new principal investigators are encouraged to present their work.

The online abstract submission process is bilingual. Abstract submissions will be accepted in both English and French. Abstracts will appear in the language of submission, and posters may be prepared and presented orally in the presenter’s language of choice.

The fifth Canadian Cancer Research Conference will be held from November 3 to 5, 2019 at the Shaw Centre, in Ottawa, Ontario. The last conference was held in 2017 with 1040 conference attendees, 696 abstract submissions, 596 poster presentations, 33 abstract selected speakers, 25 concurrent sessions and 3 plenary sessions.

Abstract submissions for oral and poster presentations will remain open until June 14, 2019.

The scientific program will consist of plenary sessions, concurrent sessions, and poster sessions featuring leading national and international researchers from across the cancer research spectrum.

Collectively, the conference’s scientific program will provide attendees with opportunities to network, learn about cutting-edge research in Canada, and present results to and receive feedback from colleagues from across the country.

Plenary session topics include:

  • Novel Cancer Immunotherapies
  • Cancer Genetics and Precision Oncology
  • Future of Cancer Research

The working list of regular sessions includes:

  • Innovations in Cancer Proteomics
  • Tumour and Immune Microenvironment
  • Pediatric and AYA Oncology
  • Stakeholder/Patient Engagement, Patient Oriented Research
  • Indigenous Populations and Cancer
  • Immunotherapy: Adoptive Cell Therapy
  • Cancer Stem Cells and Cellular Plasticity
  • Rare Cancers
  • Real World Evidence
  • Early Detection and Risk Prediction
  • Mechanisms of Cancer Resistance
  • Model Systems
  • Survivorship
  • Occupational and Environmental Exposure
  • Cancer Imaging and Profiling
  • Integration of Palliative Care Prevention
  • Consortium Based Research
  • Microbiome
  • Lessons from Aging
  • Poor Survival Cancers
  • Equity and Equality
  • Cannabis, Vaping, ECigarettes, and Tobacco
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Download the complete job posting at: https://www.pogo.ca/wp-content/uploads/2019/05/Job-Posting-Healthcare-Analyst-May-2019.pdf

The Healthcare Analyst at POGO will have strong analytic skills to solve complex data problems using SAS (Statistical Analysis System), excellent research skills, and strong project management skills to support health analytics, policy and program development and health system quality monitoring and surveillance. POGO provides a stimulating work environment for inter-institutional, multidisciplinary and multidimensional policy development. This position offers a unique opportunity to contribute to the implementation of POGO’s System Quality Indicator Initiative and other key projects to enable health system evidence-based decision making and planning integral to POGO strategic objectives. Reporting to the Senior Healthcare Analyst & Project Manager, the Healthcare Analyst will work closely with POGO Clinical/Executive Leads, program managers and staff members.

Abbreviated Candidate Education/Experience:
  • Master’s degree in Epidemiology (preferred), Public Health, Health Sciences, Health Research Methodology or recognized equivalent
  • 3-5 years of practical and related work experience in applying relevant methods and population-based data analyses to answer complex health questions and/or support health policy development
  • Experience in health system planning and/or decision support is an asset
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

INTERNAL candidates apply here. Full job posting for EXTERNAL candidates below can be found at https://career.sickkids.ca:8001/psc/CRPRD/CAREER/HRMS/c/HRS_HRAM.HRS_APP_SCHJOB.GBL?Page=HRS_APP_JBPST&Action=U&FOCUS=Applicant&SiteId=1&JobOpeningId=11049&PostingSeq=1

Are you a strategic and visionary leader who is passionate about improving efficiencies, enhancing workflow, and advancing patient care? Are you looking for an opportunity to utilize your clinical, informatics and/or clinical trials expertise to develop ways to enhance clinical trials, research and informatics?

Sick Kids is looking for a Manager to lead all aspects of the Clinical Trials and Clinical Informatics program and to develop and maintain relationships across the program. In this role, you will work closely with the unit medical director and divisional director to ensure achievement of strategic goals as they relate to decision-making, implementation, ongoing evaluation and maintenance of technologies and clinical information systems used throughout the Hematology, Oncology and Bone Marrow Transplant/Cellular Therapy program. You will have the opportunity to recognize and implement workflow process improvements involving informatics and you will develop, communicate and implement a strategic plan for the ongoing development and growth of the clinical trials program.

Abbreviated candidate education/experience (see posting for complete list):
  • Post secondary degree in a health/research related field.
  • Certified Clinical Research Professional (CCRP); strongly preferred
  • 3-5+ years of formal people management experience.
  • 3-5+ years experience with Clinical Informatics and/or Clinical Trials is a strong asset.
  • 3-5+ years of Clinical experience within Hematology, Oncology and BMT/CT is a strong asset
  • Strong relationship building skills and the ability to manage multiple stakeholders.
  • Excellent working knowledge of clinical informatics systems and workflow processes/improvements and/or of Clinical Trials Research.
  • Experience in leading, managing clinical trials in an hospital academic institution is preferred
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

For a full job description and to apply, go to: www.staffcareers.ubc.ca/33837

Job Summary

To coordinate data collection and management for the local component of the national pediatric oncology surveillance program (CYP-C: Cancer in Young People in Canada). The project is supported by a grant from the Federal Public Health Agency of Canada. Data for children diagnosed in British Columbia prior to the start of the project will be obtained from medical records and entered into a national database. The RT3 works with physicians and staff in the Data Management office and Oncology clinic. The RT3’s office is located in the Shaughnessy Building.

Qualifications–selected (see posting for full list)
  • Undergraduate degree in a relevant discipline or Graduation from a technical college or institute.
  • Health Information Technologist/Health Information Management Diploma or unit clerk certificate (preferred).
  • Certified member of SoCRA (Society of Clinical Research Associates) preferred.
  • Minimum of 3 years related experience or the equivalent combination of education and experience.
  • Knowledge of medical terminology and patient record systems required.
  • Experience in an oncology setting preferred. Demonstrated knowledge and experience with Pediatric oncology an asset.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

SURVEY LINK: https://cpacc.questionpro.ca/t/AB3unhAZB3upz8

La version française de ce courriel suit la version anglaise.

On behalf of the Canadian cancer research community, the Canadian Cancer Research Alliance (CCRA) in collaboration with Shift Health, has embarked on an exciting, highly engaging initiative to define a bold, 20-year vision for cancer research in Canada. The vision will help us to: describe what could be in the future for cancer research, align the collective research community toward common commitments and aspirations, and demonstrate what Canada needs to become if it is to continue to be an international leader in cancer research and deliver impact for patients. We would like to provide you with an opportunity to contribute to the vision by responding to a short survey.

Why should you contribute? As an individual with a vested interest in research or a member of the public who may directly or indirectly be affected by cancer, this is your opportunity to help define the future of cancer research in Canada. Your interest and participation in this initiative is greatly appreciated; we look forward to your contribution.

How can you contribute? Click on this link to access the online survey.  

The survey should take no more than 15 minutes of your time. All responses will remain confidential.

Please direct any questions to ccra.team@partnershipagainstcancer.ca.

We would greatly appreciate it if you could also share this survey with your relevant networks. You may have already received a similar request to complete this survey and if so, please disregard this email.

Au nom de la communauté canadienne de la recherche sur le cancer,  l’Alliance canadienne pour la recherche sur le cancer (ACRC) en collaboration avec Shift Health, a entrepris une initiative passionnante et très stimulante visant à définir une vision audacieuse de la recherche sur le cancer au Canada sur un horizon de 20 ans. Cette vision nous aidera à décrire l’avenir de la recherche sur le cancer, à harmoniser les engagements et les aspirations de l’ensemble de la communauté de la recherche et à démontrer ce que le Canada doit devenir s’il souhaite conserver son rôle de chef de file international dans la recherche sur le cancer et avoir des répercussions pour les patients. Nous souhaitons vous donner l’occasion de contribuer à façonner cette vision en répondant à un bref sondage.

Pourquoi apporter votre contribution? En tant que personne détenant un intérêt particulier pour la recherche ou en tant que membre du public pouvant être touché directement ou indirectement par le cancer, c’est votre chance de contribuer à définir l’avenir de la recherche sur le cancer au Canada. Votre intérêt et votre participation à cette initiative sont grandement appréciés. Nous nous réjouissons de votre contribution.

Comment pouvez-vous contribuer? Cliquez sur ce lien pour accéder le questionnaire en ligne.

Vous ne devriez pas avoir besoin de plus de 15 minutes pour répondre à ce sondage. Toutes les réponses demeureront confidentielles.

Veuillez poser vos questions à ccra.team@partnershipagainstcancer.ca.

Nous apprécierions beaucoup si vous pouviez partager cette questionnaire avec vos réseaux pertinents. Ci-vous avez déjà reçu une demande similaire de répondre à ce questionnaire, veuillez ignorer cet courrielle.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

To participate start by requesting the guidance document from hc.regulatory_review-examen_reglementaire.sc@canada.ca

Health Canada would like to inform you that we have recently launched a consultation on one of the topics of interest to you.   Opened on May 7, 2019 and will close July 21, 2019.

https://www.canada.ca/en/health-canada/programs/consultation-draft-guidance-accelerated-review-human-drug-submissions.html 

Health Canada is announcing a 75 day consultation on the draft Guidance: Accelerated Review of Human Drug Submissions. The consultation will be open for comment beginning May 7, 2019 and will close July 21, 2019.

Health Canada is committed to working with health partners in order to improve access to those drugs that are needed most by Canadians. Under the Regulatory Review of Drugs and Devices initiative, Health Canada has consulted on priority review pathways and health care system needs in order to make determinations about which products could be reviewed under shortened timelines. Feedback from these consultations has resulted in proposed modifications to both the Priority Review of Drug Submissions policy and the Notice of Compliance with Conditions policy and these are reflected under a new title: Draft Guidance: Accelerated Review of Human Drug Submissions.

The draft guidance applies to New Drug Submissions (NDS) or Supplement to New Drug Submissions (SNDS) in support of a prescription pharmaceutical, biologic or radiopharmaceutical drug product for human use for serious, life-threatening or severely debilitating diseases or conditions. Certain elements of the guidance are also applicable to generic pharmaceuticals where the innovator product has a conditional authorization.

Health Canada is seeking your feedback on the overall clarity and content of the draft guidance. In addition, it is important we hear your views on the following proposed elements which are outlined in detail in the draft guidance:

  • the single pathway for accelerated review
  • two different options for screening processes  
  • the eligibility criteria for drug product submissions seeking an accelerated review status
How to participate

To request the guidance document please email hc.regulatory_review-examen_reglementaire.sc@canada.ca

You will receive:

  • The draft guidance document, and
  • The form for your comments, by section number and line number.

Please email your comments to hc.regulatory_review-examen_reglementaire.sc@canada.ca using the form provided. All comments will be considered in the finalization of the guidance. The 75 day consultation period is from May 7, 2019 to July 21, 2019, inclusive.

Comments can also be mailed to:Regulatory Review of Drugs and Devices
Health Products and Food Branch
Health Canada
100 Eglantine Driveway, Room 3303
AL 0603B
Ottawa, ON
K1A 0K9

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Patient groups and clinicians that have not yet registered with pCODR and would like to provide input are invited to visit pCODR Registration for details on registration.

The CADTH pan-Canadian Oncology Drug Review (pCODR) is anticipating that a submission will be made for nelarabine (Atriance) for acute lymphoblastic leukemia (ALL).

The manufacturer has indicated that it will seek funding for nelarabine (Atriance) for individuals, aged 1–30 years, newly diagnosed with intermediate- or high-risk (CNS1 or CNS 2) T-ALL, stages II-IV, during upfront therapy.

The targeted deadline for receiving patient group input and registered clinician input on nelarabine (Atriance) for ALL is June 28, 2019 by 5:00 p.m. Eastern Time. This date is tentative and will be confirmed on the CADTH website once the submission has been filed by the manufacturer.

Patient group submissions can be made through the CADTH website once the submission has been filed by the manufacturer using the Patient Input Template for CADTH CDR and pCODR Programs.

Registered clinician submissions can be made through the CADTH website once the submission has been filed by the manufacturer by using the designated Clinician Input Template for nelarabine (Atriance) for ALL.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system. CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec. Learn more at: www.cadth.ca.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Find instructions for abstract submission here:
https://conference.ccra-acrc.ca/abstracts/

The Canadian Cancer Research Conference provides an excellent opportunity to present pediatric/AYA research to the cancer community. Abstract submissions from the entire spectrum of research topics are welcome. Trainees (undergraduate students, graduate students, and postdoctoral fellows) and new principal investigators are encouraged to present their work.

The online abstract submission process is bilingual. Abstract submissions will be accepted in both English and French. Abstracts will appear in the language of submission, and posters may be prepared and presented orally in the presenter’s language of choice.

The fifth Canadian Cancer Research Conference will be held from November 3 to 5, 2019 at the Shaw Centre, in Ottawa, Ontario. The last conference was held in 2017 with 1040 conference attendees, 696 abstract submissions, 596 poster presentations, 33 abstract selected speakers, 25 concurrent sessions and 3 plenary sessions.

Abstract submissions for oral and poster presentations will remain open until June 14, 2019.

The scientific program will consist of plenary sessions, concurrent sessions, and poster sessions featuring leading national and international researchers from across the cancer research spectrum.

Collectively, the conference’s scientific program will provide attendees with opportunities to network, learn about cutting-edge research in Canada, and present results to and receive feedback from colleagues from across the country.

Plenary session topics include:

  • Novel Cancer Immunotherapies
  • Cancer Genetics and Precision Oncology
  • Future of Cancer Research

The working list of regular sessions includes:

  • Innovations in Cancer Proteomics
  • Tumour and Immune Microenvironment
  • Pediatric and AYA Oncology
  • Stakeholder/Patient Engagement, Patient Oriented Research
  • Indigenous Populations and Cancer
  • Immunotherapy: Adoptive Cell Therapy
  • Cancer Stem Cells and Cellular Plasticity
  • Rare Cancers
  • Real World Evidence
  • Early Detection and Risk Prediction
  • Mechanisms of Cancer Resistance
  • Model Systems
  • Survivorship
  • Occupational and Environmental Exposure
  • Cancer Imaging and Profiling
  • Integration of Palliative Care Prevention
  • Consortium Based Research
  • Microbiome
  • Lessons from Aging
  • Poor Survival Cancers
  • Equity and Equality
  • Cannabis, Vaping, ECigarettes, and Tobacco
Read Full Article

Read for later

Articles marked as Favorite are saved for later viewing.
close
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Separate tags by commas
To access this feature, please upgrade your account.
Start your free month
Free Preview